What are the recommended initial energy settings in joules (J) for cardioversion in cases of atrial fibrillation and ventricular tachycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Energy Settings for Cardioversion of Atrial Fibrillation and Ventricular Tachycardia

For atrial fibrillation, an initial energy of 200 J is recommended with monophasic waveforms, while 100-150 J is appropriate for biphasic waveforms depending on AF duration. For ventricular tachycardia, an initial energy of 100 J is recommended for monomorphic VT, while unsynchronized defibrillation at 200 J is indicated for polymorphic VT. 1, 2

Atrial Fibrillation Cardioversion Energy Settings

Monophasic Waveform

  • Initial energy: 200 J or greater 1
  • Evidence shows significantly higher success rates with 200-360 J compared to 100 J (39% vs 14% immediate success) 1
  • Energy escalation: Increase in increments of 100 J up to maximum of 400 J 1
  • Wait at least 1 minute between shocks to avoid myocardial damage 1

Biphasic Waveform

  • Initial energy: Lower than monophasic requirements 1
    • 100 J for AF duration ≤2 days 3
    • 150 J for AF duration >2 days 3
  • Biphasic waveforms are more effective (99.1%) compared to monophasic waveforms (92.4%) 1

Atrial Flutter

  • Initial energy can be lower: 50 J with monophasic waveform 1
  • For biphasic waveform, 50 J is also appropriate for atrial flutter/atrial tachycardia 3

Ventricular Tachycardia Cardioversion Energy Settings

Monomorphic VT with Pulse

  • Initial energy: 100 J with either monophasic or biphasic waveform 2
  • Energy escalation if unsuccessful: 100 J → 150 J → 200 J → 300 J → 360 J 2
  • Synchronization is essential to avoid shock delivery during the relative refractory period 2

Polymorphic VT

  • Unsynchronized defibrillation is recommended (Class I, Level of Evidence B) 2
  • Initial energy: Higher energy (200 J) is typically used due to the unstable nature of the arrhythmia 2

Important Technical Considerations

Paddle Positioning

  • Anterior-posterior paddle configuration is generally more effective than anterior-lateral 1
  • For patients with implanted devices (pacemakers/defibrillators):
    • Position paddles as far as possible from the device 1
    • Anterior-posterior configuration is preferred to minimize risk of exit block 1
    • Device should be interrogated before and after cardioversion 1

Synchronization

  • Proper synchronization with QRS complex is critical for AF and monomorphic VT 1, 2
  • Select a lead that clearly displays both R waves and P waves 1
  • Synchronization is NOT used for polymorphic VT or VF 2

Recent Evidence on Energy Selection

Recent research suggests that higher initial energies may be more efficient:

  • A 2020 study found that maximum-fixed energy shocks (360 J) achieved higher first-shock success (75%) compared to low-escalating energy approach (34%) 4
  • However, this must be balanced against the potential for myocardial damage with higher energies 1

Pitfalls and Caveats

  1. Inadequate sedation/anesthesia: Ensure proper sedation to avoid pain during the procedure 1

  2. Failure to wait between shocks: Maintain at least 1-minute intervals between shocks to prevent myocardial damage 1

  3. Improper synchronization: Incorrect synchronization can induce more dangerous arrhythmias 1

  4. Electrolyte abnormalities: Correct potassium levels before cardioversion to ensure safety and efficacy 1

  5. Special populations: For patients with implanted devices, follow specific precautions regarding paddle placement and device interrogation 1

  6. Waveform selection: Recognize that biphasic waveforms generally require lower energy and have higher success rates than monophasic waveforms 1, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Polymorphic Ventricular Tachycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Is 120 joules (J) the starting energy setting for cardioversion of a wide complex tachycardia?
What is the recommended initial energy level for cardioversion of ventricular tachycardia, 100 joules or 150 joules?
What is the recommended initial energy setting in joules for cardioversion in atrial fibrillation (AFib) using a biphasic defibrillator?
What is the recommended initial energy setting in joules for cardioversion of atrial fibrillation using a biphasic defibrillator?
What is the usual initial energy setting for synchronized cardioversion in a hemodynamically unstable patient with atrial fibrillation of less than two days' duration?
Which thyroid function assay is least affected during the 3rd trimester of pregnancy: Total T4 (Thyroxine), Total T3 (Triiodothyronine), or Free T4 (Free Thyroxine)?
What are the brand and generic names, dosage forms, pharmacologic categories, FDA-approved indications, dosage and frequency, mechanism of action, contraindications, adverse effects, and drug interactions for Hydrochlorothiazide (hydrochlorothiazide), Premarin (conjugated estrogens), and Risperdal (risperidone)?
What autoantibody (autoantibody) binds to Thyroid-Stimulating Hormone (TSH) receptor sites on thyroid cell membranes, preventing TSH binding?
What state must a hormone be in to be biochemically active and bind to its receptor site?
What are the brand and generic names, dosage forms, pharmacologic categories, FDA-approved indications, dosage and frequency, mechanisms of action, contraindications, adverse effects, and drug interactions for Farxiga (dapagliflozin), Dyazide/Maxzide (triamterene/hydrochlorothiazide), Prometrium (progesterone), Seroquel (quetiapine), Invokana (canagliflozin), Aldactone (spironolactone), Provera (medroxyprogesterone), and Zyprexa (olanzapine)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.